Literature DB >> 10940360

Mechanisms to prevent the toxicity of chronic neuroinflammation on forebrain cholinergic neurons.

G L Wenk1, K McGann, A Mencarelli, B Hauss-Wegrzyniak, P Del Soldato, S Fiorucci.   

Abstract

Inflammatory processes may play an important role in the degeneration of basal forebrain cholinergic cells Alzheimer's disease. We infused the proinflammagen lipopolysaccharide into the basal forebrain of young rats and determined whether the chronic administration of two novel non-steroidal anti-inflammatory drugs or a pan-caspase synthesis inhibitor, z-Val-Ala-Asp(OMe)-fluoromethyl ketone (zVAD), could provide neuroprotection from the cytotoxic effects of the neuroinflammation. Chronic lipopolysaccharide infusions decreased choline acetyltransferase activity and increased the number of activated microglia within the basal forebrain region. The level of caspases 3, 8 and 9 was increased in ventral caudate/putamen. Non-steroidal anti-inflammatory drug therapy attenuated the toxicity of the inflammation upon cholinergic cells and reduced caspases 3, 8 and 9 activity in the caudate/putamen. zVAD treatment significantly decreased the levels of caspases 3, 8 and 9 but did not provide neuroprotection for the cholinergic neurons. These results suggest that prostaglandins contribute to the degeneration of forebrain cholinergic neurons in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10940360     DOI: 10.1016/s0014-2999(00)00523-9

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  12 in total

Review 1.  Nitric oxide-releasing NSAIDs: a review of their current status.

Authors:  S Fiorucci; E Antonelli; J L Burgaud; A Morelli
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

Review 2.  Inflammation and aging: can endocannabinoids help?

Authors:  Yannick Marchalant; Holly M Brothers; Gary L Wenk
Journal:  Biomed Pharmacother       Date:  2008-03-14       Impact factor: 6.529

Review 3.  Basal forebrain cholinergic dysfunction in Alzheimer's disease--interrelationship with beta-amyloid, inflammation and neurotrophin signaling.

Authors:  Reinhard Schliebs
Journal:  Neurochem Res       Date:  2005 Jun-Jul       Impact factor: 3.996

Review 4.  Cognitive Impairment, Neuroimaging, and Alzheimer Neuropathology in Mouse Models of Down Syndrome.

Authors:  Eric D Hamlett; Heather A Boger; Aurélie Ledreux; Christy M Kelley; Elliott J Mufson; Maria F Falangola; David N Guilfoyle; Ralph A Nixon; David Patterson; Nathan Duval; Ann-Charlotte E Granholm
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 5.  The significance of the cholinergic system in the brain during aging and in Alzheimer's disease.

Authors:  R Schliebs; T Arendt
Journal:  J Neural Transm (Vienna)       Date:  2006-10-13       Impact factor: 3.575

6.  The neuron-astrocyte-microglia triad in normal brain ageing and in a model of neuroinflammation in the rat hippocampus.

Authors:  Francesca Cerbai; Daniele Lana; Daniele Nosi; Polina Petkova-Kirova; Sandra Zecchi; Holly M Brothers; Gary L Wenk; Maria Grazia Giovannini
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

Review 7.  Chronic mild cerebrovascular dysfunction as a cause for Alzheimer's disease?

Authors:  Christian Humpel
Journal:  Exp Gerontol       Date:  2010-11-26       Impact factor: 4.032

Review 8.  Mouse models of Down syndrome as a tool to unravel the causes of mental disabilities.

Authors:  Noemí Rueda; Jesús Flórez; Carmen Martínez-Cué
Journal:  Neural Plast       Date:  2012-05-22       Impact factor: 3.599

9.  Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors.

Authors:  Susanna Rosi; Victor Ramirez-Amaya; Beatrice Hauss-Wegrzyniak; Gary L Wenk
Journal:  J Neuroinflammation       Date:  2004-07-07       Impact factor: 8.322

Review 10.  Rodent models of neuroinflammation for Alzheimer's disease.

Authors:  Amir Nazem; Roman Sankowski; Michael Bacher; Yousef Al-Abed
Journal:  J Neuroinflammation       Date:  2015-04-17       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.